Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma.

Cancer research·2026
Same author

Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.

Cancer immunology research·2026
Same author

Leveraging a Quality and Safety Continuous Process Improvement Framework to Increase Breast Cancer Screening Access.

Journal of the American College of Radiology : JACR·2025
Same author

A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.

Cancer·2025
Same author

KLF4 promotes a KRT13+ hillock-like state in squamous lung cancer.

bioRxiv : the preprint server for biology·2025
Same author

A tumor-binding antibody with cross-reactivity to viral antigens.

Cancer immunology, immunotherapy : CII·2025

Related Experiment Video

Updated: Jun 12, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Complement factor H autoantibodies are associated with early stage NSCLC.

Nita Amornsiripanitch1, Shaolin Hong, Michael J Campa

  • 1Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 3, 2010
PubMed
Summary

Researchers identified an autoantibody against complement factor H (CFH) as a potential biomarker for early-stage non-small cell lung cancer (NSCLC). This autoantibody was significantly more prevalent in stage I NSCLC patients, suggesting its utility in early diagnosis.

More Related Videos

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Early diagnosis of non-small cell lung cancer (NSCLC) is crucial for improving patient outcomes.
  • Identifying reliable biomarkers for early-stage NSCLC remains a significant clinical challenge.

Purpose of the Study:

  • To discover novel diagnostic biomarkers for early-stage NSCLC.
  • To investigate autoantibodies preferentially present in stage I NSCLC patients compared to advanced stages.

Main Methods:

  • Serum autoantibodies were detected using immunoblot analysis in stage I NSCLC patients.
  • The target autoantibody recognized a 150 kDa protein identified as complement factor H (CFH) via mass spectrometry.
  • Association with early-stage disease was confirmed using protein microarray analysis on a larger cohort of NSCLC patients and controls.

Main Results:

  • An autoantibody against CFH was identified.
  • Anti-CFH autoantibody was detected in 50% of stage I NSCLC patients versus 11% in late-stage patients (P=0.003) by immunoblot.
  • Protein microarray confirmed a higher incidence of anti-CFH antibody in stage I NSCLC patients (30.4%) compared to late-stage (7.4%) and controls (8.0%).

Conclusions:

  • Autoantibody against complement factor H (CFH) is associated with early-stage non-small cell lung cancer (NSCLC).
  • Anti-CFH autoantibody shows potential as a molecular marker for early NSCLC detection.